Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Cautious On Sales Projections Pending FDA, CMS Decisions On ESAs

Executive Summary

While awaiting FDA's final safety evaluation and Medicare's final coverage policy on erythropoeisis-stimulating agents, Johnson & Johnson will maintain a conservative stance on sales and earnings for the second half of the year
Advertisement

Related Content

Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
Private Payers’ ESA Policies Will Differ From Medicare NCD – Amgen
J&J Cost Savings Effort Includes Eliminating Thousands Of Pharma Positions
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
J&J Cost Savings Effort Includes Eliminating Thousands Of Pharma Positions
J&J Growth Plan Calls For Four Virology Filings In As Many Years
CMS May Take Studious Approach To Covering ESAs In Cancer Setting
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Leukemia Trials Need Broader Populations, FDA/ASH Workshop Suggests
Advertisement
UsernamePublicRestriction

Register

PS048596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel